US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer

Date: January 22, 2011
Pages: 59
Price:
US$ 8,900.00 US$ 1,200.00
License [?]:
Publisher: The Assessment Group
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: U088EDD1EF7EN
Leaflet:

Download PDF Leaflet

US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
Executive Summary

CHAPTER 1: INTRODUCTION

Table 1. Treatment Options in Metastatic Breast Cancer

CHAPTER 2: RESPONDENT DEMOGRAPHICS

Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

CHAPTER 3: TREATMENT OF A PATIENT WITH TRIPLE NEGATIVE METASTATIC BREAST CANCER

Figure 3.1Choice of chemotherapy regimen, triple negative metastatic breast cancer
Figure 3.2 Single chemotherapy choices, triple negative metastatic breast cancer
Figure 3.3 Combination chemotherapy choices, triple negative metastatic breast cancer
Figure 3.4 Factors influencing treatment of triple negative metastatic breast cancer
Figure 3.5 Confidence managing patient with triple negative metastatic breast cancer
Figure 3.6 Other agents appropriate to include in treatment of triple negative metastatic breast cancer
Figure 3.7 Treatment of progressive triple negative metastatic breast cancer
Figure 3.8 Single chemotherapy agent, progressive triple negative metastatic breast cancer
Figure 3.9 Combination chemotherapy, progressive triple negative metastatic breast cancer
Figure 3.10 Barriers to optimal treatment of progressive triple negative metastatic breast cancer
Figure 3.11 Changing therapy to manage neuropathy
Figure 3.12 Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.13 Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation
Figure 3.14 Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation

CHAPTER 4: TREATMENT OF PATIENT WITH TRIPLE POSITIVE METASTATIC BREAST CANCER

Figure 4.1 Next step for patient with triple positive metastatic breast cancer
Figure 4.2 Treatment of progressive disease, triple positive metastatic breast cancer
Figure 4.3 Single chemotherapy choices for progressive triple positive metastatic breast cancer
Figure 4.4 Combination chemotherapy, progressive triple positive metastatic breast cancer
Figure 4.5 Factors influencing treatment of progressive triple positive metastatic breast cancer
Figure 4.6 Treatment regimen for continued progression of triple positive metastatic breast cancer
Figure 4.7 Decisions regarding the use of lapatinib in progressive triple positive metastatic breast cancer
Figure 4.8 Management of progressive disease, triple positive metastatic breast cancer

CHAPTER 5: PATIENT WITH ER/PR POSITIVE HER2NEU NEGATIVE METASTATIC BREAST CANCER

Figure 5.1 Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.2 Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.3 Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.4 Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 5.5 Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer

CHAPTER 6: PATIENT WITH METASTATIC BREAST CANCER WITH MULTIPLE COMORBIDITIES

Figure 6.1 Confidence managing patient with metastatic breast cancer with multiple comorbidities
Figure 6.2 Barriers to managing patient, metastatic breast cancer with multiple comorbidities
Figure 6.3 Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities
Figure 6.4 Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities
Figure 6.5 Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities

CHAPTER 7: SUMMARY

Appendix A: Survey Instrument
Skip to top


Ask Your Question

US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: